{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T19:03:23Z","timestamp":1795201403615,"version":"4.10.3"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T00:00:00Z","timestamp":1544227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Osteomyelitis is a challenging infection that can involve 4\u20136 weeks of intravenous (IV) antibiotics. Dalbavancin, approved for acute bacterial skin and skin structure infections, has potent activity against gram-positive pathogens. This study assessed the efficacy and safety of dalbavancin as a 2-dose regimen for osteomyelitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study was a randomized, open-label, comparator-controlled trial in adults with a first episode of osteomyelitis defined by clinical symptoms, radiologic findings, and elevated C-reactive protein. Patients were randomized 7:1 to dalbavancin (1500 mg IV on days 1 and 8) or standard of care (SOC) for osteomyelitis (oral or IV) per investigator judgment for 4\u20136 weeks. The primary endpoint was clinical response at day 42, defined as recovery without need for additional antibiotics in the clinically evaluable (CE) population. Clinical response was also assessed at day 21, 6 months, and 1 year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty patients were randomized to dalbavancin (n = 70) or SOC (n = 10). All had baseline debridement; Staphylococcus aureus was the most common pathogen (60% of patients). Clinical cure at day 42 was seen in 65\/67 (97%) and 7\/8 (88%) patients in the dalbavancin group and SOC group in the CE population, respectively. Clinical response was similar in the dalbavancin group at day 21 (94%), 6 months, and 1 year (96%). Treatment-emergent adverse events occurred in 10 patients in the dalbavancin group; no patient discontinued treatment due to an adverse event.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A 2-dose regimen of weekly dalbavancin is effective and well tolerated for the treatment of osteomyelitis in adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02685033.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofy331","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T05:03:45Z","timestamp":1544245425000},"source":"Crossref","is-referenced-by-count":195,"title":["Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety"],"prefix":"10.1093","volume":"6","author":[{"given":"Urania","family":"Rappo","sequence":"first","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailaja","family":"Puttagunta","sequence":"additional","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadym","family":"Shevchenko","sequence":"additional","affiliation":[{"name":"Orthopedic and Trauma Department, Cherkasy Regional Hospital, Cherkasy, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Shevchenko","sequence":"additional","affiliation":[{"name":"Orthopedic and Trauma Department, Cherkasy Regional Hospital, Cherkasy, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Jandourek","sequence":"additional","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Medical Affairs, Allergan plc, Jersey City, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Suen","sequence":"additional","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mas Casullo","sequence":"additional","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Melnick","sequence":"additional","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Miceli","sequence":"additional","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Kovacevic","sequence":"additional","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan","family":"De Bock","sequence":"additional","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W","family":"Dunne","sequence":"additional","affiliation":[{"name":"Clinical Development, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,10]]},"reference":[{"key":"2020081003363305200_CIT0001","article-title":"Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions","volume":"31:e00084-17","author":"Kavanagh","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2020081003363305200_CIT0002","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020081003363305200_CIT0003","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"2020081003363305200_CIT0004","first-page":"CD004439","article-title":"Antibiotics for treating chronic osteomyelitis in adults","volume":"9","author":"Conterno","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2020081003363305200_CIT0005","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/cid\/ciu410","article-title":"Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008\u20132011: significant geographic variation in community-onset infections","volume":"59","author":"David","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020081003363305200_CIT0006","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020081003363305200_CIT0007","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020081003363305200_CIT0008","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020081003363305200_CIT0009","volume-title":"Full Prescribing Information","author":"Dalvance (dalbavancin)","year":"2017"},{"key":"2020081003363305200_CIT0010","volume-title":"Full Prescribing Information","author":"Xydalba (dalbavancin)","year":"2016"},{"key":"2020081003363305200_CIT0011","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020081003363305200_CIT0012","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"2020081003363305200_CIT0013","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020081003363305200_CIT0014","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","article-title":"Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020081003363305200_CIT0015","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ijantimicag.2017.12.011","article-title":"Dalbavancin in-vitro activity obtained against gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011\u20132016)","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020081003363305200_CIT0016","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081003363305200_CIT0017","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijid.2004.09.009","article-title":"Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?","volume":"9","author":"Lazzarini","year":"2005","journal-title":"Int J Infect Dis"},{"key":"2020081003363305200_CIT0018","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkv357","article-title":"Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis","volume":"71","author":"Barnea","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081003363305200_CIT0019","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020081003363305200_CIT0020","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am J Case Rep"},{"key":"2020081003363305200_CIT0021","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s13063-015-1098-y","article-title":"Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial","volume":"16","author":"Li","year":"2015","journal-title":"Trials"},{"key":"2020081003363305200_CIT0022","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1128\/AAC.01504-08","article-title":"Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis","volume":"53","author":"Euba","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081003363305200_CIT0023","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jac\/dkl281","article-title":"Effect of dalbavancin on the normal intestinal microflora","volume":"58","author":"Nord","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2020081003363305200_CIT0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/IPC.0000000000000640","article-title":"Lipoglycopeptides, outpatient parenteral antibiotic therapy, and the infectious disease doctor\u2014moving forward","volume":"26","author":"Poretz","year":"2018","journal-title":"Infect Dis Clin Prac"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/1\/ofy331\/33575910\/ofy331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/1\/ofy331\/33575910\/ofy331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T07:37:16Z","timestamp":1597045036000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy331\/5235615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,10]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy331","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,12,10]]},"article-number":"ofy331"}}